328 related articles for article (PubMed ID: 26967384)
21. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
22. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
23. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis.
Deng M; Zha J; Zhao H; Jia X; Shi Y; Li Z; Fu G; Yu L; Fang Z; Xu B
Exp Cell Res; 2020 May; 390(1):111934. PubMed ID: 32126236
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth.
Lepore A; Choy PM; Lee NCW; Carella MA; Favicchio R; Briones-Orta MA; Glaser SS; Alpini G; D'Santos C; Tooze RM; Lorger M; Syn WK; Papakyriakou A; Giamas G; Bubici C; Papa S
Hepatology; 2021 Nov; 74(5):2561-2579. PubMed ID: 34048060
[TBL] [Abstract][Full Text] [Related]
25. RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis.
Yu GY; Wang X; Zheng SS; Gao XM; Jia QA; Zhu WW; Lu L; Jia HL; Chen JH; Dong QZ; Lu M; Qin LX
Cell Physiol Biochem; 2018; 47(3):1152-1166. PubMed ID: 29913454
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
[TBL] [Abstract][Full Text] [Related]
27. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway.
Wang Y; Deng M; Chen Q; Li Y; Guo X; Shi P; He L; Xie S; Yu L; Zhang H; Xu B
Eur J Pharmacol; 2019 Jan; 843():145-153. PubMed ID: 30423319
[TBL] [Abstract][Full Text] [Related]
28. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Dana P; Fujikawa S; Matsuda K; Ohkuma K; Kudo E; Kraiklang R; Wongkham C; Wongkham S; Okada S
Tumour Biol; 2016 Jul; 37(7):9023-35. PubMed ID: 26762407
[TBL] [Abstract][Full Text] [Related]
30. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
[TBL] [Abstract][Full Text] [Related]
31. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.
Cadamuro M; Brivio S; Mertens J; Vismara M; Moncsek A; Milani C; Fingas C; Cristina Malerba M; Nardo G; Dall'Olmo L; Milani E; Mariotti V; Stecca T; Massani M; Spirli C; Fiorotto R; Indraccolo S; Strazzabosco M; Fabris L
J Hepatol; 2019 Apr; 70(4):700-709. PubMed ID: 30553841
[TBL] [Abstract][Full Text] [Related]
32. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
Deng M; Zha J; Jiang Z; Jia X; Shi Y; Li P; Chen XL; Fang Z; Du Z; Xu B
J Transl Med; 2018 Feb; 16(1):47. PubMed ID: 29490645
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma.
Tang L; Tan YX; Jiang BG; Pan YF; Li SX; Yang GZ; Wang M; Wang Q; Zhang J; Zhou WP; Dong LW; Wang HY
Clin Cancer Res; 2013 Apr; 19(8):2014-24. PubMed ID: 23493353
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.
Fan M; Zhang J; Wang Z; Wang B; Zhang Q; Zheng C; Li T; Ni C; Wu Z; Shao Z; Hu X
Breast Cancer Res Treat; 2014 Jan; 143(1):141-51. PubMed ID: 24292957
[TBL] [Abstract][Full Text] [Related]
35. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
[TBL] [Abstract][Full Text] [Related]
36. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation.
Zhang Z; Lai GH; Sirica AE
Hepatology; 2004 Apr; 39(4):1028-37. PubMed ID: 15057907
[TBL] [Abstract][Full Text] [Related]
37. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.
Yang B; Tong R; Liu H; Wu J; Chen D; Xue Z; Ding C; Zhou L; Xie H; Wu J; Zheng S
Int J Oncol; 2018 Apr; 52(4):1235-1245. PubMed ID: 29532867
[TBL] [Abstract][Full Text] [Related]
38. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Qiu H; Li J; Liu Q; Tang M; Wang Y
Cell Cycle; 2018; 17(10):1235-1244. PubMed ID: 29886786
[TBL] [Abstract][Full Text] [Related]
39. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
[TBL] [Abstract][Full Text] [Related]
40. Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma.
Sueoka H; Hirano T; Uda Y; Iimuro Y; Yamanaka J; Fujimoto J
Surgery; 2014 Apr; 155(4):640-9. PubMed ID: 24582495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
